Literature DB >> 28913321

Mixed Tumor in Deep Lobe and Versatility of Acellular Dermal Matrix.

Jin Hwan Byun1, Jung Soo Lim1, Hye Kyung Lee1.   

Abstract

Frey's syndrome and infra-auricular depressed deformities are the ones of the most common complications that can occur after total parotidectomy. We report 1 case of pleomorphic adenoma occurred in the deep lobe that obtained good results from using acellular dermal matrix (ADM) after total parotidectomy. A 24-year-old man visited the hospital with oval shape mass in right mandibular angle which of 4 cm in size was found in the deep lobe of right parotid gland from Magnetic resonance imaging scanning and a pleomorphic adenoma was suspected. A total parotidectomy was performed while preserving the facial nerve. The material known as ADM were placed in the depressed part from where the mass was removed, and the site was sutured. The surgery site was healed well without any complications such as Frey's syndrome or infra-auricular depressed deformities. The pathological result was confirmed as pleomorphic adenoma. In addition to these advantages, it does not have little potential of deformation by the gravity after the surgery, and there is no restraint on circulation, which makes fabrication free and each deformation into various shapes can be described as another advantage of the reconstruction using the ADM.

Entities:  

Keywords:  Acellular dermis; Parotid neoplasm; Pleomorphic adenoma; Sweating, gustatory

Year:  2017        PMID: 28913321      PMCID: PMC5556895          DOI: 10.7181/acfs.2017.18.2.132

Source DB:  PubMed          Journal:  Arch Craniofac Surg        ISSN: 2287-1152


  12 in total

1.  Prevention of Frey Syndrome With Temporal Fascia Flap in Parotidectomy.

Authors:  Xiao-Ming Dai; Hua Liu; Yi-Song Li; Sheng-Guo Ji; Shao-Hua Qin; Liu Liu
Journal:  Ann Plast Surg       Date:  2015-12       Impact factor: 1.539

Review 2.  A review of tumours of the deep lobe of the parotid salivary gland.

Authors:  R J Carr; J E Bowerman
Journal:  Br J Oral Maxillofac Surg       Date:  1986-06       Impact factor: 1.651

3.  The use of human acellular dermal matrix in the prevention of infra-auricular depressed deformities and Frey's syndrome following total parotidectomy.

Authors:  Wen Luo; Xiaohui Zheng; Lin Chen; Wei Jing; Wei Tang; Jie Long; Weidong Tian; Lei Liu
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-02-25

4.  Transplanted acellular allograft dermal matrix. Potential as a template for the reconstruction of viable dermis.

Authors:  S A Livesey; D N Herndon; M A Hollyoak; Y H Atkinson; A Nag
Journal:  Transplantation       Date:  1995-07-15       Impact factor: 4.939

5.  Use of AlloDerm implant to prevent frey syndrome after parotidectomy.

Authors:  Uttam K Sinha; Daryoush Saadat; Carolyn M Doherty; Dale H Rice
Journal:  Arch Facial Plast Surg       Date:  2003 Jan-Feb

Review 6.  Pleomorphic adenoma of the parotid: formal parotidectomy or limited surgery?

Authors:  Peter Zbären; Vincent Vander Poorten; Robert L Witt; Julia A Woolgar; Ashok R Shaha; Asterios Triantafyllou; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito
Journal:  Am J Surg       Date:  2012-10-11       Impact factor: 2.565

7.  Recurrent pleomorphic adenoma of the parotid gland: Institutional experience and review of the literature.

Authors:  Yasmin Abu-Ghanem; Aviram Mizrachi; Aron Popovtzer; Nora Abu-Ghanem; Raphael Feinmesser
Journal:  J Surg Oncol       Date:  2016-07-29       Impact factor: 3.454

8.  Use of allogenic acellular dermal matrix in prevention of Frey's syndrome after parotidectomy.

Authors:  Wei Min Ye; Han Guang Zhu; Jia Wei Zheng; Xu Dong Wang; Wen Zhao; Lai Ping Zhong; Zhi Yuan Zhang
Journal:  Br J Oral Maxillofac Surg       Date:  2008-06-10       Impact factor: 1.651

9.  Deep lobe parotid pleomorphic adenoma presenting as obstructive sleep apnoea.

Authors:  Omar Mulla; Frank Agada; David Dawson; Sanjai Sood
Journal:  BMJ Case Rep       Date:  2013-04-03

10.  Extracapsular dissection for clinically benign parotid lumps: reduced morbidity without oncological compromise.

Authors:  M McGurk; B L Thomas; A G Renehan
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.